Lumira-backed G1 Therapeutics goes public with $105 mln issue

U.S. clinical-stage oncology company G1 Therapeutics Inc priced its recently filed initial public offering to raise US$105 million, not including its greenshoe option. It began trading today on Nasdaq's Global Select Market under the symbol GTHX. Research Triangle Park, North Carolina-based G1 develops novel small-molecule therapies for the treatment of cancer. Since its founding in 2008, the company has raised nearly US$100 million in funding from several investors, including Canadian life sciences venture capital firm Lumira Capital.

CanadaNorth AmericaBriefs